DaVita Inc. (NYSE:DVA) Shares Sold by Sippican Capital Advisors

Sippican Capital Advisors decreased its holdings in DaVita Inc. (NYSE:DVA) by 4.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,465 shares of the company’s stock after selling 529 shares during the quarter. Sippican Capital Advisors’ holdings in DaVita were worth $1,716,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Harvard Management Co. Inc. purchased a new stake in shares of DaVita during the second quarter valued at approximately $55,115,000. Lazard Asset Management LLC lifted its holdings in DaVita by 147.3% in the 1st quarter. Lazard Asset Management LLC now owns 256,872 shares of the company’s stock valued at $35,460,000 after acquiring an additional 153,008 shares during the last quarter. Andra AP fonden raised its holdings in DaVita by 9.0% during the 2nd quarter. Andra AP fonden now owns 192,300 shares of the company’s stock worth $26,647,000 after buying an additional 15,800 shares during the period. abrdn plc increased its holdings in shares of DaVita by 1.2% in the 3rd quarter. abrdn plc now owns 189,065 shares of the company’s stock valued at $30,719,000 after purchasing an additional 2,180 shares during the period. Finally, Jupiter Asset Management Ltd. increased its holdings in DaVita by 146.7% in the first quarter. Jupiter Asset Management Ltd. now owns 187,177 shares of the company’s stock worth $25,840,000 after buying an additional 111,311 shares during the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

Insider Activity at DaVita

In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the transaction, the insider now directly owns 83,011 shares in the company, valued at $12,137,038.31. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the sale, the insider now directly owns 83,011 shares in the company, valued at approximately $12,137,038.31. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Javier Rodriguez sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the transaction, the chief executive officer now directly owns 837,835 shares of the company’s stock, valued at approximately $138,284,666.75. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 173,482 shares of company stock worth $27,387,069. Insiders own 2.00% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Truist Financial increased their price objective on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. TD Cowen boosted their target price on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. UBS Group boosted their price target on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Finally, Bank of America upped their target price on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, DaVita has an average rating of “Hold” and a consensus price target of $159.00.

DaVita Trading Up 0.3 %

Shares of NYSE:DVA traded up $0.48 during trading on Thursday, hitting $141.70. The company had a trading volume of 52,707 shares, compared to its average volume of 813,510. DaVita Inc. has a one year low of $76.17 and a one year high of $168.50. The company has a debt-to-equity ratio of 9.94, a current ratio of 1.16 and a quick ratio of 1.12. The stock has a market cap of $11.89 billion, a price-to-earnings ratio of 15.03, a price-to-earnings-growth ratio of 0.90 and a beta of 0.87. The company has a fifty day simple moving average of $158.21 and a two-hundred day simple moving average of $146.02.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a net margin of 6.86% and a return on equity of 77.00%. The company had revenue of $3.26 billion during the quarter, compared to analyst estimates of $3.25 billion. During the same period last year, the firm earned $2.85 EPS. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. As a group, equities analysts forecast that DaVita Inc. will post 9.99 earnings per share for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.